CULLINAN THERAPEUTICS, INC. Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect
CULLINAN THERAPEUTICS, INC. (CGEM) reported Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect of -$9.69 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-06.
Financial Statements › Cash Flow
us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect · last filed 2026-08-06
- CULLINAN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2026-03-31 was -$13.25M.
- CULLINAN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2025-03-31 was -$6.35M.
- CULLINAN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2024-03-31 was -$24.21M.
- CULLINAN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for the quarter ending 2023-03-31 was -$34.02M, a 308.17% decline year-over-year.
- CULLINAN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2025 was $5.33M.
- CULLINAN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2024 was -$15.43M.
- CULLINAN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2023 was -$57.72M, a 159.89% decline from fiscal 2022.
- CULLINAN THERAPEUTICS, INC. cash, cash equivalents, restricted cash and restricted cash equivalents, period increase (decrease), excluding exchange rate effect for fiscal 2022 was $96.38M.
| Period end | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 3 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 6 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 9 month | Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Excluding Exchange Rate Effect 12 month |
|---|---|---|---|---|
| 2026-06-30 | -$9.69M 10-Q · filed 2026-08-06 | |||
| 2026-03-31 | -$13.25M 10-Q · filed 2026-05-07 | |||
| 2025-12-31 | $5.33M 10-K · filed 2026-03-10 | |||
| 2025-09-30 | $20.33M 10-Q · filed 2025-11-06 | |||
| 2025-06-30 | -$10.19M 10-Q · filed 2026-08-06 | |||
| 2025-03-31 | -$6.35M 10-Q · filed 2026-05-07 | |||
| 2024-12-31 | -$15.43M 10-K · filed 2026-03-10 | |||
| 2024-09-30 | $3.65M 10-Q · filed 2025-11-06 | |||
| 2024-06-30 | $16.59M 10-Q · filed 2025-08-07 | |||
| 2024-03-31 | -$24.21M 10-Q · filed 2025-05-08 | |||
| 2023-12-31 | -$57.72M 10-K · filed 2025-02-27 | |||
| 2023-09-30 | -$91.31M 10-Q · filed 2024-11-07 | |||
| 2023-06-30 | -$14.32M 10-Q · filed 2024-08-08 | |||
| 2023-03-31 | -$34.02M 10-Q · filed 2024-05-15 | |||
| 2022-12-31 | $96.38M 10-K · filed 2024-03-14 | |||
| 2022-09-30 | $182.88M 10-Q · filed 2023-11-08 | |||
| 2022-06-30 | $293.79M 10-Q · filed 2023-08-10 | |||
| 2022-03-31 | $16.34M 10-Q · filed 2023-05-11 | |||
| 2021-12-31 | -$108.42M 10-K · filed 2023-03-09 | |||
| 2021-09-30 | -$80.09M 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | -$44.53M 10-Q · filed 2022-08-10 | |||
| 2021-03-31 | $125.34M 10-Q · filed 2022-05-16 | |||
| 2020-12-31 | $104.95M 10-K · filed 2022-03-17 | |||
| 2020-09-30 | -$21.95M 10-Q · filed 2021-11-09 | |||
| 2020-06-30 | -$12.15M 10-Q · filed 2021-08-10 | |||
| 2020-03-31 | -$17.87M 10-Q · filed 2021-05-14 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Monte Rosa Therapeutics, Inc. (GLUE) | United States | $1.002B | -12.81 |
| Odyssey Therapeutics, Inc. (ODTX) | United States | $0.960B | |
| MeiraGTx Holdings plc (MGTX) | United States | $1.061B | 16.10 |
| Vor Biopharma Inc. (VOR) | United States | $1.091B | 1.60 |
| Sana Biotechnology, Inc. (SANA) | United States | $0.886B | -4.92 |
| Candel Therapeutics, Inc. (CADL) | United States | $0.885B | -8.86 |
| Attovia Therapeutics, Inc. (ATTO) | United States | $0.828B | |
| Solid Biosciences Inc. (SLDB) | United States | $0.802B | -5.07 |
| Replimune Group, Inc. (REPL) | United States | $1.186B | -3.13 |
| 4D Molecular Therapeutics, Inc. (FDMT) | United States | $0.733B | -4.10 |